SCNI
Scinai Immunotherapeutics Ltd.
Key Financials
Net Income
$-5796000
↑ 29.4%
Operating Income
$-11061000
↓ 1.8%
Shareholders' Equity
$-1760000.00
↓ 279.2%
EPS (Diluted)
$-0.01
↑ 50.0%
Cash & Equivalents
$14.1M
↓ 19.0%
Total Assets
$27.1M
↓ 15.5%
Operating Cash Flow
$-7265000.00
↑ 2.2%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 7/9/2026 | View on SEC |
| SCHEDULE 13G/A | 7/1/2026 | View on SEC |
| 4 | 6/18/2026 | View on SEC |
| 4 | 6/18/2026 | View on SEC |
| 6-K | 6/17/2026 | View on SEC |
| 6-K | 6/15/2026 | View on SEC |
| 6-K | 6/8/2026 | View on SEC |
| EFFECT | 5/19/2026 | View on SEC |
| 424B3 | 5/19/2026 | View on SEC |
| CORRESP | 5/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | SCNI |
| Company Name | Scinai Immunotherapeutics Ltd. |
| CIK | 1611747 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | L3 |
| Phone | 972-8-9302529 |